文献速递免疫规划传染病防控与疫情报告

加拿大国家疫苗安全网络-COVID-19疫苗(CANVAS-COVID)研究中参与者报告的免疫接种后神经系统事件

Participant-reported neurological events following immunization in the Canadian National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study.
PubMed 文献 · Vaccine · 2024-10-16

CANVAS-COVID通过在线调查对接种COVID-19疫苗后7天内及未接种对照进行主动监测,纳入15,273名未接种对照和不同剂次疫苗接种者。结果显示ChAdOx1第一剂后神经系统事件风险升高(调整OR 2.3,95%CI 1.2-4.3),mRNA疫苗任一剂次后未见风险升高,结果支持COVID-19疫苗安全性。

要点

  • ChAdOx1第一剂后神经系统事件风险较对照升高(调整OR 2.3,95%CI 1.2-4.3)。
  • mRNA疫苗任一剂次后神经系统事件风险未见升高。
  • 基于参与者的免疫接种后不良事件监测是上市后监测的有用组成部分。

核心结论

  • 结果支持COVID-19疫苗的安全性,同时证实ChAdOx1第一剂与神经系统事件之间的关联。
  • 基于参与者的免疫接种后不良事件监测是上市后监测项目的有用组成部分。

研究设计与样本

  • 加拿大国家疫苗安全网络(CANVAS)在COVID-19疫苗 campaign 期间开展了基于参与者的主动免疫接种后不良事件监测。
  • 参与者被邀请完成在线调查,报告接种COVID-19疫苗后7天内或调查前7天内(未接种对照)阻止日常活动和/或需要就医的健康事件,7个月后发送随访调查。
  • 神经系统事件定义为报告的最严重症状为以下至少1项的健康事件:麻木/刺痛、味觉或嗅觉丧失、视力丧失、面部无力/瘫痪、癫痫发作、手臂或腿部无力/瘫痪、意识模糊、人格或行为改变、排尿或排便困难。
  • 数据从CANVAS-COVID数据库提取分析。
  • 完成调查回复者包括15,273名未接种对照、758,619名第一剂接种者、406,884名第二剂接种者和126,586名第三剂接种者。

主要发现

  • 神经系统事件发生率从第一剂ChAdOx1接种者的15.9(95%CI 13.6-18.4)/10,000到第三剂mRNA-1273和BNT162b2接种者的8.4(6.5-10.8)/10,000和7.9(5.7-11.0)/10,000不等。
  • 调整年龄、性别、既往SARS-CoV-2感染和基线健康状况的多变量回归显示,第一剂ChAdOx1接种者较对照神经系统事件风险升高(调整OR 2.3,95%CI 1.2-4.3),但mRNA疫苗任一剂次后未见风险升高。
  • 第一剂ChAdOx1后麻醉/感觉异常风险升高(aOR 4.7,95%CI 1.7-13.1),任一剂次mRNA疫苗后一致但未达统计学显著升高。
  • 任一剂次mRNA疫苗接种者较对照嗅觉/味觉丧失风险降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The Canadian National Vaccine Safety Network (CANVAS) conducted active participant-based surveillance for adverse events following immunization during the COVID-19 vaccine campaign. This study evaluated the association between COVID-19 vaccination and neurological adverse events. METHODS: Participants were invited to complete online surveys to report health events that prevented daily activities and/or required medical attention within 7 days after COVID-19 vaccination or 7 days prior to the survey (unvaccinated controls); follow-up surveys were sent 7 months later. Neurological events were health events where the most severe symptom reported was ≥1 of: numbness/tingling, loss of taste or smell, vision loss, facial weakness/paralysis, seizure, weakness/paralysis of arms or legs, confusion, change in personality or behavior, or difficulty with urination or defecation. Data were extracted from the CANVAS-COVID database for analysis. RESULTS: Completed survey responses were received from 15,273 unvaccinated controls, 758,619 dose 1 recipients, 406,884 dose 2 recipients, and 126,586 dose 3 recipients. Rates of neurological events ranged from 15.9 (95 % CI 13.6-18.4) per 10,000 dose 1 ChAdOx1 recipients to 8.4 (6.5-10.8) and 7.9 (5.7-11.0) per 10,000 dose 3 mRNA-1273 and BNT162b2 recipients, respectively. Multivariable regression adjusted for age, sex, previous SARS-CoV-2 infection, and baseline health status showed an increased risk of neurological event among ChAdOx1 dose 1 recipients versus controls (adjusted OR 2.3, 95 % CI 1.2-4.3), but not among mRNA vaccine recipients after any dose. Risk of anaesthesia/paresthesia were increased following ChAdOx1 dose 1 (aOR 4.7, 1.7-13.1), and consistently but not statistically significantly higher following any dose of either mRNA vaccine. Risk of loss of smell/taste was decreased among recipients of any dose of either mRNA vaccine versus controls. CONCLUSIONS: The results support the safety of COVID-19 vaccines while confirming reported associations between ChAdOx1 dose 1 and neurological events. Participant-based AEFI surveillance is a useful component of post-market surveillance programs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Top KA, Shulha HP, Muller MP, et al. Participant-reported neurological events following immunization in the Canadian National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study. Vaccine. 2024. PMID: 39413493. doi:10.1016/j.vaccine.2024.126445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。